M&A Deal Summary |
|
---|---|
Date | 2021-06-16 |
Target | Alydia Health |
Sector | Medical Products |
Buyer(s) | Organon |
Deal Type | Add-on Acquisition |
Deal Value | 240M USD |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Sector | Healthcare Services |
Revenue | 8.1B USD (2020) |
Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, to focus on improving the health of women throughout their lives. The company has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the reproductive health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in future growth opportunities in women’s health, including business development. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast-growing international markets. Organon is based in Jersey City, New Jersey.
DEAL STATS | # |
---|---|
Overall | 1 of 2 |
Sector (Medical Products) | 1 of 1 |
Type (Add-on Acquisition) | 1 of 2 |
State (California) | 1 of 1 |
Country (United States) | 1 of 1 |
Year (2021) | 1 of 2 |
Size (of disclosed) | 1 of 2 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2021-11-11 |
Forendo Pharma
Turku, Finland Forendo Pharma is a clinical-stage drug development company focused on novel treatments in women’s health. Forendo Pharma is based in Turku, Finland. |
Buy | $75M |